TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female, 45 to 80 years of age, in good general health~* postmenopausal ≥2 years, surgically or naturally~* body mass index less than or equal to 32 kg/m\^2 at screening~Exclusion Criteria:~* no use within 3 months prior, nor use for more than 1 month at any time within 6 months of: glucocorticoids, anabolic steroids, estrogens, selective estrogen-receptor modulators (SERMs), or estrogen-related drugs, progestins, calcitonin, vitamin D supplements (\>1200 IU per day), calcitriol, calcidiol, or alfacalcidol at any dose, any bisphosphonate. fluoride (≥10 mg/day), strontium (≥50 mg/day), parathyroid hormone, investigational bone active agents.~* allergic or abnormal reactions to bisphosphonates~* history of cancer within 5 years, excluding squamous and basal cell carcinoma with 6 month remission~* positive pregnancy test~* no depot injection \>10,000 IU vitamin D in previous 9 months.~* no history of GI disease that requires medication, or history of Crohn's disease, ulcerative colitis, diverticular disease, polyps, or surgery that could have changed GI structure or motility.~* no history of frequent diarrhea or constipation that requires regular laxative use.~* no history of alcohol or durg abuse, hyperparathyroidism, cancer previous 5 years, major surgery within 1 month prior to screening, diabetes, uncontrolled hypertension, cardiovascular, hepatic, renal or GI disease.~* no active hyperthyroidism, osteomalacia, use of anticonvulsant medication, or allergic reaction to bisphosphonates

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 150 mg (Type: ACTIVE_COMPARATOR): 150 mg risedronate tablet IRBB (immediate release before breakfast) administered orally at least 30 minutes before breakfast.
- 75 mg (Type: EXPERIMENTAL): 75 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast
- 100 mg (Type: EXPERIMENTAL): 100 mg risedronate tablet DRFB (delayed release following breakfast) administered orally immediately after ingesting breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 to 80 years of age;~* Previously met the preliminary criteria of American Rheumatism Associatio (ARA) for the classification of acute gout arthritis of primary gout;~* Subjects with history of gout, initiating or currently on urate lowering; therapy who are at risk of gout flare.~Exclusion Criteria:~* Acute gout flare within 2 weeks prior to the screening visit and during the screening visit;~* Persistent chronic or active infections;~* History of an allergic reaction to allopurinol;~* History or presence of cancer within 5 years of the Screening Visit;;;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Two subcutaneous injections of Placebo (for Rilonacept) as a loading dose on Day 1 followed by a single injection once a week (qw) from Week 1 to Week 15.
- Rilonacept 160 mg (Type: EXPERIMENTAL): Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) as a loading dose on Day 1, followed by a single 160 mg injection of Rilonacept qw from Week 1 to Week 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* American Society of Anesthesiologists (ASA) Class \>=4~* Creatinine clearance (CLCR) \< 30 mL/min and clinical indication for dialysis~* Hospitalization at Intensive Care Unit (ICU) and scheduled for a (surgical) procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium~* Scheduled for a (surgical) procedure in supine position~* Written informed consent (of the legal representative)~Exclusion Criteria:~* Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant hepatic dysfunction~* Known or suspected to have a (family) history of malignant hyperthermia~* Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Have already participated in a sugammadex trial~* Have participated in another clinical trial, not preapproved by NV Organon, within 30 days of study entry~* Females who are pregnant\*~* Females who are breast-feeding \* In females pregnancy will be excluded both from medical history and by a human chorionic gonadotropin (hCG) test within 24 hours before surgery except in females who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or an hysterectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): IV single bolus dose of 4.0 mg/kg sugammadex

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women equal or elder 40 years of age~* Either acute ischaemic stroke or high-risk TIA as defined here and randomisation occurring within 24 hours after onset of symptoms~Key Exclusion Criteria:~* Planned use of antithrombotic therapy in addition to study medication including antiplatelets (eg, open label ASA, GPIIb/IIIa inhibitors, clopidogrel, ticlopidine, prasugrel, dipyridamole, ozagrel, cilostazol) and anticoagulants (eg, warfarin, oral thrombin and factor Xa inhibitors, bivalirudin, hirudin, argatroban, unfractionated and low molecular weight heparins). - Any history of atrial fibrillation, ventricular aneurysm or suspicion of cardioembolic pathology for TIA or stroke. - Planned carotid, cerebrovascular, or coronary revascularisation that requires halting study medication within 7 days of randomisation. - Receipt of any intravenous or intra-arterial thrombolysis or mechanical thrombectomy within 24 hours prior to randomisation - History of previous symptomatic non-traumatic intracerebral bleed at any time (asymptomatic microbleeds do not qualify), gastrointestinal (GI) bleed within the past 6 months, or major surgery within 30 days.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- ticagrelor (Type: EXPERIMENTAL): None
- Acetylsalicylic acid (ASA) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients having a confirmed diagnosis of cancer and are planned to receive platinum chemotherapy with a minimum of 8 weeks on study and a maximum of 6 or 12 cycles~* Eastern Cooperative Oncology Group (a scale used by researchers to represent the level of activity that a patient is capable of) score of 0 (able to carry out all normal activity without restriction) to 3 (capable of only limited self-care, confined to bed or chair \>50% of waking hours)~* life expectancy of \>=5 months~* have a hemoglobin value of \<=7.5 grams per deciliter at any time during or prior to chemotherapy~Exclusion Criteria:~* Patients having clinically significant disease/dysfunction of the pulmonary, cardiovascular, endocrine, neurological, gastrointestinal, or genitourinary systems that is not due to cancer or chemotherapy (this disease/dysfunction is only an exclusion criterion if it causes an expected early withdrawal from the study)~* uncontrolled high blood pressure~* history of seizures~* untreated iron, folate, or vitamin B12 deficiency~* received androgen (e.g., testosterone) therapy within 2 months of study entry, had a major illness within 7 days of study entry, or a major infection within 1 month of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Center-involved macular edema secondary to central retinal vein occlusion (CRVO) for no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical coherence tomography (OCT)~* Adults ≥ 18 years~* Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters) in the study eye~Exclusion Criteria:~* Any prior treatment with anti-VEGF agents in the study eye (Pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of systemic anti-angiogenic medications~* Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye~* CRVO disease duration \> 9 months from date of diagnosis~* Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1~* Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) (Type: EXPERIMENTAL): Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.
- Sham treatment (Type: SHAM_COMPARATOR): Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Performance Evaluation of the Calcivis System

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must be 6 years or older~2. Patient must have one unrestored, accessible, free smooth buccal surface on a canine or incisor, away from the gingival surface identified with no visible lesions (coded ICDAS 0) and/or~3. Patient must have one unrestored, accessible, erupting or erupted molar or premolar with a visible lesion identified as (coded ICDAS 2 or 3) in a plaque stagnation area~4. Patient and / or parent or guardian must be willing and able to give written informed consent~5. Patient and / or parent or guardian must be willing and able to adhere to study schedule~Exclusion Criteria:~1. Any patient with recent tooth bleaching (within previous two weeks of imaging with the Calcivis System)~2. Any patient having on-going re-mineralization treatment including, but not limited to high concentration prescription fluoride toothpaste~3. Any patient with a fixed orthodontic appliance~4. Any patient currently taking part in a clinical research study, or has taken part in a clinical research study in the previous three months~5. Pregnant and / or nursing mothers

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Sound and unsound teeth (Type: OTHER): Sound (ICDAS 0) canines or incisors and unsound (ICDAS 2 or 3) molars or pre-molars - imaging with the Calcivis System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 30 to 80 years of age, inclusive.~* Diagnosis of idiopathic PD meeting the United Kingdom Parkinson's disease Society Brain Bank criteria.~* Levodopa-induced dyskinesia present greater than 25% of the day as per MDS-UPDRS.~* Dyskinesia of at least moderate severity as per MDS-UPDRS~* Amantadine and Monoamine Oxidase (MAO) inhibitors must be discontinued at least three weeks prior to randomization.~* Subjects currently receiving anti-parkinsonian medications, including all Levodopa preparations are eligible provided they have been on a stable dose of these medications for at least 1 month prior to randomization.~* Concomitant use of antidepressants such as selective serotonin reuptake inhibitors are allowed, provided the dose has been stable for at least 1 month prior to randomization.~Exclusion Criteria:~* Subject had a prior surgery for PD except Deep Brain Stimulation (Deep Brain Stimulation must not have been performed within one year of screening)~* Hoehn and Yahr score of 5 when off.~* Subject with Cognitive impairment and/or history of psychiatric manifestations or active hallucinations.~* Subjects with any history of complete heart block, QTc prolongation, or torsades de pointes.~* Subjects with any family history of congenital QT interval prolongation syndrome.~* Subjects with history of postural syncope, or any history of unexplained syncope within the last 12 months.~* Subjects with a history of substance and/or alcohol abuse within the past 2 years.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AVP-923-45 (Type: EXPERIMENTAL): AVP-923-45 twice daily for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice a day for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients for whom written informed consent has been signed by the patients themselves (if aged 18 years and over) or by parents(s) or legal guardian for patients under 18 years of age.~2. Patients aged between 4 and 60 years (inclusive) who are able to comply with the protocol. It is justified to include children because they represent more than 50% of VL cases.~3. Patients with clinical signs and symptoms of VL and diagnosis confirmed by visualization of parasites in tissue samples (spleen, lymph node or bone marrow) on microscopy.~Exclusion Criteria:~1. Patients who have received any anti-leishmanial drug in the last 6 months.~2. Patients with a negative splenic / lymph node / bone marrow smears.~3. Patients with a clinical contraindication to splenic/lymph node/ bone marrow aspirates.~4. Patients with severe protein and or caloric malnutrition (Kwashiokor or marasmus)~5. Patients with previous hypersensitivity reaction to SSG or aminoglycosides.~6. Patients suffering from a concomitant severe infection such as TB or any other serious underlying disease (cardiac, renal, hepatic) which would preclude evaluation of the patients response to study medication.~7. Patients suffering from other conditions associated with splenomegaly such as schistosomiasis.~8. Patients with previous history of cardiac arrhythmia or an abnormal ECG~9. Patients who are pregnant or lactating.~10. Patients with haemoglobin \< 5gm/dl.~11. Patients with WBC \< 1 x 10³/mm³.~12. Patients with platelets \< 40,000/mm³.~13. Patients with liver function tests more than three times the normal range~14. Patients with serum creatinine outside the normal range for age and gender~15. Patients with pre-existing clinical hearing loss.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Sodium Stibogluconate (30 days)
- 2 (Type: EXPERIMENTAL): Paromomycin Sulphate (21 days)
- 3 (Type: EXPERIMENTAL): Sodium Stibogluconate + Paromomycin Sulphate (17 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan 80mg Non-responder Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Essential hypertensive patients~  * If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be \>=90 and \>=114 mmHg~ * If not taking any antihypertensive drugs, mean seated DBP must be \>=95 and \>=114 mmHg~* Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.~Exclusion criteria:~* Patients taking 3 or more antihypertensive drugs at signing the informed consent form~* Patients with known or suspected secondary hypertension~* Patients with clinically relevant cardiac arrhythmia~* Congestive heart failure with New York Heart Association (NYHA) functional class III-IV~* Patients with recent cardiovascular events~* Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form~* Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy~* Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors~* Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs~* Patients with hepatic and/or renal dysfunction~* Pre-menopausal women who are nursing or pregnant

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan and amlodipine FDC (Type: EXPERIMENTAL): once a daily
- Telmisartan monotherapy (Type: ACTIVE_COMPARATOR): once a daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Homeless or marginally housed~* Score of greater than 13 on the Beck Depression Inventory (BDI)~* DSM-IV diagnosis of major depressive disorder, dysthymia, or minor depressive disorder~* Considered by the reviewing psychiatrist to benefit from antidepressant therapy~* Willing to take antidepressant medication or, if currently taking medication, willing to change medications if deemed appropriate~* Consents to coordinate with the primary medical provider~* Speaks English~Exclusion Criteria:~* Signs and symptoms consistent with diagnosis of dementia, as defined by DSM-IV~* Current substance abuse disorder requiring immediate residential or inpatient treatment~* At risk for suicide~* Presence of signs and symptoms consistent with psychotic depression, as defined by DSM-IV, warranting immediate hospitalization~* Any condition or use of any medication that may make simultaneous use of antidepressant medication unsafe~* Currently prescribed antidepressant therapy and in psychiatric treatment (treated by a psychiatrist within 3 months prior to study entry)~* Pregnant~* Bipolar disorder~* Current psychotic disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Participants receiving storefront directly observed therapy of anti-depressants (Fluoxetine)
- Control (Type: NO_INTERVENTION): Participants receiving referral to mental health follow-up with the UCSF AIDS Health Project

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete